Clinical Indication ID & Name
Primary immunodeficiency or monogenic inflammatory bowel disease
Test Group
Immunology
Specialties
Test code
R15.4
Test name
N/A
Target genes
Primary immunodeficiency (398)
Test scope
n/a
Test method/ technology
WGS
Optimal Family Structure
n/a
Eligibility Criteria
Suspected primary immunodeficiency diagnosed by a consultant immunologist
Indications include patients with any of the eight International Union of Immunological Societies (IUIS) categories of primary immunodeficiency:
1. Combined immunodeficiency, with or without associated features and abnormal T cell numbers or function. This may include abnormal naïve T cells, TRECs, repertoire, proliferations (e.g. PHA), reversed Cd4/8 ratio or increased gamma delta T cells)
2. Predominantly antibody deficiencies with low or absent vaccine responses
3. Diseases of immune dysregulation including haemophagocytic lymphohistiocytosis (HLH)
4. Congenital defects of phagocyte number, function or both. This should be evidenced by low
phagocytic204 numbers and/or abnormal DHR/NBT/phagocytosis/L selectin shedding, Cd11a,b,c or CD18, or abnormal migration or adhesion
5. Defects in intrinsic and innate immunity
6. Autoinflammatory disorders
7. Complement deficiencies with abnormal complement function
8. Testing under these criteria would also include young children with inflammatory bowel disease, defined as: bloody diarrhoea, severe failure to thrive and severe intestinal inflammation with histology consistent with chronic inflammatory intestinal pathology, of onset under 6 years of age OR
Suspected monogenic IBD diagnosed by a consultant paediatric gastroenterologist, gastroenterologist or immunologist
1. Infantile onset IBD less then 2 years onset; very early onset IBD (<6years of onset) with
severe course (requiring biologics or surgery) or relevant comorbidities and extraintestinal manifestations
2. Testing may occasionally be appropriate outside these criteria following discussion in a
specialist MDT, (for example paediatric or young adult IBD with documented severity criteria e.g. relevant family history, comorbidities and extraintestinal manifestations such as infection susceptibility).
Commissioning group
Specialised
Overlapping idications
• R16 Severe combined immunodeficiency with adenosine deaminase deficiency test should be used in individuals with ADA deficiency • R234 Severe combined immunodeficiency with PNP deficiency test should be used in individuals with PNP deficiency • R235 Severe combined immunodeficiency with gamma chain deficiency test should be used in individuals with low or absent gamma chain or low or absent STAT5 pTyr to IL-2,7, and 15 • R17 Lymphoproliferative syndrome with low or absent SAP expression test should be used in individuals with absent SAP expression • R232 Lymphoproliferative syndrome with low or absent perforin expression test should be used in individuals with absent perforin expression • R18 Lymphoproliferative syndrome with low or absent XIAP expression test should be used in individuals with absent XIAP expression • R19 Autoimmune lymphoproliferative syndrome with defective apoptosis test should be used in individuals with defective Fas-mediated apoptosis, elevated alpha double negative T cells, elevated sFAS or elevated vitamin B12 • R233 Agammaglobulinaemia with low or absent BTK expression test should be used in individuals with absent BTK expression • R20 Wiskott-Aldrich syndrome test should be used in individuals with a likely diagnosis of WAS • R204 Amyloidosis with no identifiable cause test should be used in cases with confirmed amyloidosis
Address for samples/request forms
North Thames GLH, Rare & Inherited Disease Genomic Laboratory
Specimen Reception, Level 5 Barclay House, 37 Queen Square,
London WC1N 3BH
Contact with queries
Supporting documents
Rare Disese WGS Clinician pack
Education resources
n/a
Service updates
n/a
Request form download
Consent record
See consent guidance in test request form
Sample requirements
See sample guidance in test request form